Cargando…

Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans

BACKGROUND: Proteomics of atypical phenotypes may help unravel cardiovascular disease mechanisms. AIM: We aimed to prospectively screen the proteome of four types of individuals: with or without coronary artery disease (CAD), each with or without multiple risk factors. Associations with individual r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrannini, Ele, Manca, Maria Laura, Ferrannini, Giulia, Andreotti, Felicita, Andreini, Daniele, Latini, Roberto, Magnoni, Marco, Williams, Stephen A., Maseri, Attilio, Maggioni, Aldo P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855064/ https://www.ncbi.nlm.nih.gov/pubmed/35187107 http://dx.doi.org/10.3389/fcvm.2021.790289

Ejemplares similares

Why Do High-Risk Patients Develop or Not Develop Coronary Artery Disease? Metabolic Insights from the CAPIRE Study
por: Deidda, Martino, et al.
Publicado: (2022)

Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events
por: Magnoni, Marco, et al.
Publicado: (2022)

IgG N-Glycosylation Is Altered in Coronary Artery Disease
por: Radovani, Barbara, et al.
Publicado: (2023)

Osteopontin as Candidate Biomarker of Coronary Disease despite Low Cardiovascular Risk: Insights from CAPIRE Study
por: Carbone, Federico, et al.
Publicado: (2022)

Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program
por: Ferrannini, Giulia, et al.
Publicado: (2022)

Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?
por: Ferrannini, Ele, et al.
Publicado: (2021)

Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE
por: Ferrannini, Giulia, et al.
Publicado: (2023)

Erratum. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646
por: Ferrannini, Ele, et al.
Publicado: (2021)

Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study
por: Posch, Maximilian G., et al.
Publicado: (2022)

Response to Comment on: Ferrannini. Learning From Glycosuria. Diabetes 2011;60:695–696
por: Ferrannini, Ele
Publicado: (2011)

Learning From Glycosuria
por: Ferrannini, Ele
Publicado: (2011)

A Journey in Diabetes: From Clinical Physiology to Novel Therapeutics: The 2020 Banting Medal for Scientific Achievement Lecture
por: Ferrannini, Ele
Publicado: (2021)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia: Experiences from the randomized, controlled SOCOGAMI trial
por: Fortin, Elena, et al.
Publicado: (2023)

Impact of Different Bariatric Surgical Procedures on Insulin Action and β-Cell Function in Type 2 Diabetes
por: Ferrannini, Ele, et al.
Publicado: (2009)

Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
por: Katsiki, Niki, et al.
Publicado: (2020)

Role of anatomical location, cellular phenotype and perfusion of adipose tissue in intermediary metabolism: A narrative review
por: Camastra, Stefania, et al.
Publicado: (2022)

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
por: Polidori, David, et al.
Publicado: (2014)

Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study
por: Fortin, Elena, et al.
Publicado: (2022)

Redefining the Diagnosis of Diabetes Using Glycated Hemoglobin
por: Fonseca, Vivian, et al.
Publicado: (2009)

Prevalence, prescriptions, outcomes and costs of type 2 diabetes patients with or without prior coronary artery disease or stroke: a longitudinal 5-year claims-data analysis of over 7 million inhabitants
por: Maggioni, Aldo Pietro, et al.
Publicado: (2021)

Precision Phenomapping of Acute Coronary Syndromes to Improve Patient Outcomes
por: Andreotti, Felicita, et al.
Publicado: (2021)

Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
por: Natali, Andrea, et al.
Publicado: (2021)

Prognostic implications of high-sensitivity cardiac troponin T assay in a real-world population with non-ST-elevation acute coronary syndrome()
por: Magnoni, Marco, et al.
Publicado: (2018)

Relation Between Plasma Proteomics Analysis and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease
por: Dregoesc, Mihaela Ioana, et al.
Publicado: (2022)

Renal Glucose Handling: Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2013)

Fixed‐ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß‐cell function in people with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2022)

COVID-19 trials in Italy: A call for simplicity, top standards and global pooling
por: Maggioni, Aldo P., et al.
Publicado: (2020)

Methodological education in response to the quality of COVID-19 publications
por: Andreotti, Felicita, et al.
Publicado: (2021)

Recurrence of Cardiovascular Events in Patients With Type 2 Diabetes : Epidemiology and risk factors
por: Giorda, Carlo B., et al.
Publicado: (2008)

Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset
por: Ferrannini, Ele, et al.
Publicado: (2010)

Human Insulin Resistance Is Associated With Increased Plasma Levels of 12α-Hydroxylated Bile Acids
por: Haeusler, Rebecca A., et al.
Publicado: (2013)

New Trial Evidence on Heart Failure: Highlights from the European Society of Cardiology Congress 2021
por: Ferrannini, Giulia, et al.
Publicado: (2022)

Comparative Platelet Releasate Proteomic Profiling of Acute Coronary Syndrome versus Stable Coronary Artery Disease
por: Maguire, Patricia B., et al.
Publicado: (2020)

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
por: Ferrannini, Ele, et al.
Publicado: (2010)

Short Course of Insulin Treatment versus Metformin in Newly Diagnosed Patients with Type 2 Diabetes
por: Seghieri, Marta, et al.
Publicado: (2018)

Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
por: Shin, Yujin, et al.
Publicado: (2020)

The effect of age on longitudinal measures of beta cell function and insulin sensitivity during the progression of early stage type 1 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2022)

β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes
por: Gitelman, Stephen E., et al.
Publicado: (2023)

Antiplatelet Therapy during the First Year after Acute Coronary Syndrome in a Contemporary Italian Community of over 5 Million Subjects
por: Calabria, Silvia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p725ud2ldf838hjsaju763vj98